GleamWall
中文EN

GERN GERON CORP

Pharmaceutical Preparations · Nasdaq · SEC CIK 886744 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY40.2%
TTM EPS YoY33.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-20.1%
ROA-8.7%
ROIC (approx.)-8.9%
Asset turnover—

Leverage & solvency

Liabilities / assets57.0%
Debt / equity0.53x
Current ratio6.31x
Interest coverage-1.11x

Cash quality & payout

Operating cash flow / net income1.89x
Accruals ratio7.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$71.43M$103.74M
SG&A expense$159.26M$145.73M
Operating income-$68.58M-$173.73M
Interest expense$32.66M$18.50M
Pretax income-$83.42M-$174.52M
Income tax$75,000$449,000
Net income-$83.50M-$174.57M
EBITDA-$68.11M-$173.19M
EPS (basic)-0.13-0.27
EPS (diluted)-0.13-0.27
Weighted avg. shares (diluted)666.66M646.03M
Balance sheet
Cash & equivalents$77.56M$79.02M
Short-term investments—$327.55M
Receivables$36.99M$35.95M
Inventory$116.64M$38.71M
Current assets$520.27M$490.99M
PP&E, net$884,000$1.31M
Total assets$570.54M$593.78M
Current liabilities$111.54M$88.30M
Short-term debt—$0
Long-term debt$119.55M$118.48M
Total debt$119.55M$118.48M
Total liabilities$344.67M$313.46M
Shareholders' equity$225.87M$280.32M
Net debt$41.99M$39.46M
Shares outstanding639.86M606.39M
Cash flow statement
Operating cash flow-$111.04M-$218.62M
Capital expenditure—$680,000
Free cash flow—-$219.30M
Investing cash flow$107.25M-$106.00M
Financing cash flow$2.27M$334.37M
Depreciation & amortization$474,000$546,000
Stock-based compensation$26.66M$31.18M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.